Peer Reviewed
Therapeutics clinic
An update on the medical management of benign prostatic hypertrophy
Abstract
Medical therapy for men with symptomatic benign prostatic hypertrophy is continuously evolving. The two major classes of medications used in the treatment of affected men are selective 1-adrenergic receptor antagonists and 5-reductase inhibitors. Depending on the type and severity of urinary symptoms, adjunctive therapies may also be used.
Key Points
Benign prostatic hypertrophy (BPH) is defined as the proliferation of smooth muscle and epithelial cells within the prostate resulting in an enlarged gland. BPH is a common condition of increasing importance in light of our ageing population, and can have a significant impact on a man’s quality of life.
Picture credit: © SPL.
Purchase the PDF version of this article
Already a subscriber? Login here.